IDH1/IDH2
EstablishedIDH1/IDH2 mutations define distinct favorable-risk AML and glioma subtypes, each with its own FDA-approved targeted drug.
These two genes are metabolic enzymes that, when mutated, disrupt normal cell development in both a blood cancer (AML) and certain brain tumors (gliomas). Both mutations now have their own specific targeted pills, and in gliomas, this single mutation status is used to define an entirely different tumor category with a different prognosis, not just a modifier of the same disease.
Isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are metabolic enzymes; cancer-associated mutations produce an abnormal oncometabolite (2-hydroxyglutarate) that disrupts normal cell differentiation, occurring in a meaningful subset of acute myeloid leukemia and gliomas.
IDH1 or IDH2 mutations in AML are generally classified as favorable-to-intermediate risk under 2024 ELN criteria, and both mutations now have specific FDA-approved targeted oral drugs — ivosidenib for IDH1 and enasidenib for IDH2 — that work by blocking the abnormal oncometabolite production, restoring normal cell maturation.
Detected via PCR or NGS panel on bone marrow or blood in AML, or on tumor tissue in glioma; IDH mutation status in gliomas is now a core part of WHO CNS tumor classification, distinguishing IDH-mutant gliomas (generally better prognosis) from IDH-wildtype glioblastoma (generally worse prognosis) as fundamentally different disease categories, not just a prognostic modifier.
IDH1-mutated AML patients treated with azacitidine plus ivosidenib show consistently favorable outcomes per 2024 ELN data; a notable AML side effect risk exists with these drugs — differentiation syndrome, a potentially serious inflammatory complication requiring prompt steroid treatment when it occurs during therapy.
IDH mutation status is now a core WHO classification criterion for gliomas, defining fundamentally different tumor categories.
- Blood. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.